FrancophonIA/ELRC3.0 huggingface dataset:
English: The efficacy of infliximab was assessed in two multicenter, randomised, double-blind studies: SPIRIT and EXPRESS.
Croatian: Djelotvornost infliksimaba ispitivana je u dva multicentrična, randomizirana, dvostruko slijepa, klinička ispitivanja: SPIRIT i EXPRESS.
English: It is unknown whether infliximab is excreted in human milk or absorbed systemically after ingestion.
Croatian: Nije poznato izlučuje li se infliksimab u majčino mlijeko niti dolazi li do sustavne apsorpcije nakon hranjenja.
English: • You are allergic (hypersensitive) to proteins that come from mice.
Croatian: • Ako ste alergični (preosjetljivi) na bjelančevine mišjeg podrijetla.
English: Delayed hypersensitivity
Croatian: Reakcije kasne preosjetljivosti
English: Remicade should be administered intravenously.
Croatian: Remicade se primjenjuje intravenski.
English: Overall, a higher proportion of patients receiving infliximab monotherapy experienced an infusion-related reaction compared to patients receiving infliximab with concomitant immunomodulators.
Croatian: Sveukupno je reakciju vezanu uz infuziju imao veći udio bolesnika koji su primali infliksimab kao monoterapiju u odnosu na bolesnike koji su primali infliksimab istodobno s imunomodulatorima.
English: Group 1 received 5 mg/kg infliximab.
Croatian: Skupina 1 primala je dozu od 5 mg/kg infliksimaba.
English: Remicade is indicated for treatment of severe, active Crohn's disease, in children and adolescents aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies.
Croatian: Remicade je indiciran za liječenje teške, aktivne Crohnove bolesti u djece i adolescenata u dobi između 6 i 17 godina, koji nisu odgovorili na konvencionalnu terapiju uključujući kortikosteroid, imunomodulator i primarnu nutritivnu terapiju, te onih koji ne podnose takve vrste terapija ili su im one kontraindicirane.
English: All patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis (e.g. persistent cough, wasting/weight loss, low-grade fever) appear during or after Remicade treatment.
Croatian: Sve bolesnike treba uputiti da se jave liječniku ako se tijekom ili nakon liječenja lijekom Remicade pojave znakovi/simptomi koji bi mogli ukazivati na tuberkulozu (npr. perzistirajući kašalj, gubitak tjelesne težine, subfebrilnost).
English: At week 16, 47 placebo patients with < 10% improvement from baseline in both swollen and tender joint counts were switched to infliximab induction (early escape).
Croatian: U 16. je tjednu 47 bolesnika koji su primali placebo i u odnosu na početno stanje imali < 10% poboljšanja s obzirom na broj otečenih i bolnih zglobova prebačeno na uvodnu terapiju infliksimabom (rani bijeg).
English: Efficacy and safety of infliximab were assessed in two multicenter, double-blind, placebo-controlled studies in patients with active ankylosing spondylitis (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] score ≥ 4 and spinal pain ≥ 4 on a scale of 1-10).
Croatian: Djelotvornost i sigurnost infliksimaba ocjenjivale su se u dva multicentrična, dvostruko slijepa, placebom kontrolirana ispitivanja u bolesnika s aktivnim ankilozantnim spondilitisom (rezultat ≥ 4 prema Bath indeksu aktivnosti ankilozantnog spondilitisa [engl.
English: Signs include yellowing of the skin and eyes, dark-brown coloured urine, pain or swelling in the upper right side of the stomach area, joint pain, skin rashes, or fever.
Croatian: Znakovi uključuju žutu boju kože i bjeloočnica, tamnosmeđu boju mokraće, bol ili oticanje u gornjem desnom dijelu trbuha, bol u zglobovima, kožne osipe ili vrućicu.
English: Because of the nature of the adverse reactions seen with combination of etanercept and anakinra therapy, similar toxicities may also result from the combination of anakinra and other TNF-blocking agents.
Croatian: Zbog prirode nuspojava primijećenih kod istodobne primjene etanercepta i anakinre, slična toksičnost mogla bi se javiti i kod istodobne primjene anakinre i nekog drugog inhibitora TNFα.
English: In clinical studies, mild or moderate elevations of ALT and AST have been observed in patients receiving Remicade without progression to severe hepatic injury.
Croatian: U kliničkim ispitivanjima opažen je blagi do umjereni porast vrijednosti ALT-a i AST-a u bolesnika koji su primali Remicade, ali nije došlo do razvoja teškog oštećenja jetre.
English: If these medicines do not work well enough, you will be given Remicade to treat your disease.
Croatian: Ako ti lijekovi ne djeluju dovoljno dobro, za liječenje bolesti dobit ćete Remicade.
English: During treatment with Remicade
Croatian: Tijekom liječenja lijekom Remicade
English: Therefore, the combination of Remicade and anakinra is not recommended.
Croatian: Stoga se ne preporučuje kombinirana primjena lijeka Remicade i anakinre.
English: Continued therapy with a shortened interval should be carefully considered in those patients who show no evidence of additional therapeutic benefit after a change in dosing interval.
Croatian: Treba pažljivo razmotriti nastavak terapije uz skraćeni interval u onih bolesnika koji ne pokažu znakove dodatnog poboljšanja nakon promjene intervala između doza.
English: The most common adverse event was worsening of ulcerative colitis, the incidence of which was higher in patients on the q12 week vs. the q8 week dosing regimen.
Croatian: Najčešći štetni događaj bilo je pogoršanje ulceroznog kolitisa, čija je incidencija bila viša u bolesnika koji su terapiju primali svakih 12 tjedana nego u onih koji su je primali svakih 8 tjedana.
English: Patients received 5 mg/kg infliximab- or placebo-infusions at weeks 0, 2 and 6 followed by maintenance therapy every 8 weeks through week 22 in the placebo group and through week 46 in the infliximab group.
Croatian: Bolesnici su primili infuziju infliksimaba u dozi od 5 mg/kg ili placeba u 0., 2. i 6. tjednu, nakon čega je slijedila terapija održavanja svakih 8 tjedana koja je trajala do 22. tjedna u placebo skupini, odnosno do 46. tjedna u skupini koja je primala infliksimab.
English: In clinical studies 36% of infliximab-treated patients were treated for infections compared with 25% of placebo-treated patients.
Croatian: U kliničkim su se ispitivanjima infekcije pojavile u 36% bolesnika liječenih infliksimabom, u odnosu na 25% bolesnika koji su dobivali placebo.
English: Remicade is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or PUVA (see section 5.1).
Croatian: Remicade je indiciran za liječenje umjerene do teške plak psorijaze u odraslih bolesnika u kojih je druga sustavna terapija, uključujući ciklosporin, metotreksat ili PUVA terapiju, nedjelotvorna, kontraindicirana ili je bolesnici ne podnose (vidjeti dio 5.1).
English: Clinical remission at week 30
Croatian: Klinička remisija u 30. tjednu
English: • Signs of low blood counts such as persistent fever, bleeding or bruising more easily, small red or purple spots caused by bleeding under the skin, or looking pale.
Croatian: • Znakove smanjenog broja krvnih stanica kao što su stalna vrućica, krvarenje ili lakše stvaranje modrica, male crvene ili ljubičaste točkice uzrokovane krvarenjem ispod kože ili bljedilo.
English: Patient Reminder Card
Croatian: Kartica s podsjetnikom za bolesnika
English: At week 2, all patients were assessed for clinical response and randomised to one of 3 treatment groups; a placebo maintenance group, 5 mg/kg maintenance group and 10 mg/kg maintenance group.
Croatian: U drugom tjednu ispitivanja procijenjen je klinički odgovor u svih bolesnika koji su potom randomizirani u jednu od 3 terapijske skupine: skupinu koja je kao terapiju održavanja primala placebo, skupinu koja je primala infuziju u dozi od 5 mg/kg i skupinu koja je primala infuziju u dozi od 10 mg/kg.
English: PGA of cleared (0) or minimal (1) PGA of cleared (0), minimal (1), or mild (2) All nails cleared
Croatian: PGA čist (0) ili minimalan (1) PGA čist (0), minimalan (1) ili blag (2) Svi nokti bez psorijatičnih promjena 10. tjedan
English: A greater proportion of patients in the combined infliximab treatment group were able to discontinue corticosteroids while remaining in clinical remission compared to the placebo treatment group at both week 30 (22.3% vs. 7.2%, p < 0.001, pooled ACT 1 & ACT 2 data) and week 54 (21.0% vs. 8.9%, p = 0.022, ACT1 data).
Croatian: Udio bolesnika koji su mogli prestati uzimati kortikosteroide i pritom ostati u kliničkoj remisiji bio je veći u zbirnoj skupini bolesnika liječenih infliksimabom u odnosu na skupinu koja je primala placebo, kako u 30. tjednu (22,3% naspram 7,2%, p < 0,001, zbirni podaci iz ispitivanja ACT 1 i ACT 2) tako i u 54. tjednu (21,0% naspram 8,9%, p = 0,022, podaci iz ispitivanja ACT 1).
English: • The medicine will be given as an infusion (drip) (over 2 hours) into one of your veins, usually in your arm. After the third treatment, your doctor may decide to give your dose of Remicade over 1 hour.
Croatian: • Lijek će se primijeniti infuzijom (ukapavanjem) tijekom 2 sata u jednu od vena, obično na ruci.
English: Rheumatoid arthritis Crohn's disease Paediatric Crohn's disease
Croatian: Reumatoidn i artritis Crohnova bolest Crohnova bolest u pedijatrijski h bolesnika
English: In post-marketing spontaneous reporting, infections are the most common serious adverse reaction.
Croatian: Nakon stavljanja lijeka u promet infekcije su bile najčešća spontano prijavljena ozbiljna nuspojava.
English: In SPIRIT, the proportion of patients achieving PASI 75 at week 10 was 71.7% in the 3 mg/kg infliximab group, 87.9% in the 5 mg/kg infliximab group, and 5.9% in the placebo group (p < 0.001).
Croatian: U ispitivanju SPIRIT, udio bolesnika koji su postigli PASI 75 u 10. tjednu bio je 71,7% u skupini koja je primala infliksimab u dozi od 3 mg/kg, 87,9% u skupini koja je primala infliksimab u dozi od 5 mg/kg te 5,9% u skupini koja je primala placebo (p < 0,001).
English: Paediatric patients on infliximab may receive concurrent vaccinations, except for live vaccines (see sections 4.5 and 4.6).
Croatian: Pedijatrijski bolesnici koji se liječe infliksimabom mogu istodobno primati cjepiva, osim živih cjepiva (vidjeti dijelove 4.5 i 4.6).
English: Infliximab + AZA Combination Therapy
Croatian: Kombinirana terapija infliksimab + AZA
English: • Fluid in the lining of the heart (pericardial effusion)
Croatian: • nakupljanje tekućine u srčanoj ovojnici (perikardijalna efuzija)
English: • Children should receive recommended vaccinations before starting Remicade treatment.
Croatian: • Prije započinjanja liječenja lijekom Remicade djeca trebaju primiti preporučena cjepiva.
English: • Cervical cancer
Croatian: • rak grlića maternice
English: All patients received methotrexate (optimised to 20 mg/wk by week 8) and either placebo, 3 mg/kg or 6 mg/kg infliximab at weeks 0, 2, and 6 and every 8 weeks thereafter.
Croatian: Svi su bolesnici primili metotreksat (doza optimizirana na 20 mg tjedno do 8. tjedna) te ili placebo ili 3 mg/kg odnosno 6 mg/kg infliksimaba 0., 2. i 6. tjedna ispitivanja, a zatim svakih 8 tjedana.
English: • Signs of a lung problem such as coughing, breathing difficulties or tightness in the chest.
Croatian: • Znakove problema s plućima kao što su kašalj, otežano disanje ili stezanje u prsnom košu.
English: • Liver problem that causes yellowing of the skin or eyes (jaundice)
Croatian: • jetrene tegobe koje uzrokuju žutilo kože ili bjeloočnica (žutica)
English: Percentage of subjects in clinical remission and sustained remission Clinical remission at week 8
Croatian: Postotak ispitanika u kliničkoj remisiji i održanoj remisiji Klinička remisija u 8. tjednu
English: • Signs of an immune system disorder such as joint pain or a rash on cheeks or arms that is sensitive to the sun (lupus) or cough, shortness of breath, fever or skin rash (sarcoidosis).
Croatian: • Znakove poremećaja imunološkog sustava kao što su bol u zglobovima ili osip na obrazima ili rukama osjetljiv na sunce (lupus) ili kašalj, nedostatak zraka, vrućica ili kožni osip (sarkoidoza).
English: It is recommended that therapeutic infectious agents not be given concurrently with Remicade (see section 4.4).
Croatian: Ne preporučuje se istodobna primjena terapijskih infektivnih agenasa s lijekom Remicade (vidjeti dio 4.4).
English: How to store Remicade
Croatian: Kako čuvati Remicade
English: The proportions of patients with mucosal healing at week 26 were significantly greater in the infliximab plus AZA combination (43.9%, p < 0.001) and infliximab monotherapy groups (30.1%, p = 0.023) compared to the AZA monotherapy group (16.5%).
Croatian: Udio bolesnika kojima je sluznica zacijelila u 26. tjednu bio je značajno veći u skupini koja je primala infliksimab + AZA (43,9%, p < 0,001) i skupini koja je primala monoterapiju infliksimabom (30,1%, p = 0,023) nego u skupini koja je primala monoterapiju AZA (16,5%).
English: HAQ change from baseline over time e (patients evaluated) Mean ± SD
Croatian: Promjena HAQ-a od početne vrijednosti e (evaluirani bolesnici)
English: • Balance problems or feeling dizzy
Croatian: • poteškoće s ravnotežom ili omaglica
English: Table 7 Effects on response rate, data from ACCENT II (week-14 responders) ACCENT II (week-14 responders) Placebo Maintenance (n = 99)
Croatian: Tablica 7 Učinci na stopu odgovora, podaci iz ACCENT II (bolesnici s odgovorom u 14. tjednu) ACCENT II (bolesnici s odgovorom u 14. tjednu)
English: • Bleeding in the stomach or intestines, diarrhoea, indigestion, heartburn, constipation
Croatian: • krvarenje u želucu ili crijevima, proljev, loša probava, žgaravica, zatvor
English: Fewer subjects underwent colectomy in the 5 mg/kg infliximab group (28/242 or 11.6% [N.S.]) and the 10 mg/kg infliximab group (18/242 or 7.4% [p = 0.011]) than in the placebo group
Croatian: Kolektomiji je podvrgnut manji broj bolesnika koji su primali infliksimab u dozama od 5 mg/kg (28/242 ili 11, 6% [N.S.]) i 10 mg/kg (18/242 ili 7,4% [p = 0, 011]) nego onih koji su primali placebo (36/244; 14,8%).
English: By week 26, twenty weeks after the last induction dose, 30% of patients in the 5 mg/kg group and 13.8% of patients in the 3 mg/kg group were PASI 75 responders.
Croatian: Do 26. tjedna, dvadeset tjedana nakon posljednje doze uvodne terapije, odgovor PASI 75 imalo je 30% bolesnika koji su primali dozu od 5 mg/kg i 13,8% bolesnika koji su primali dozu od 3 mg/kg.
English: Patients on infliximab may receive concurrent vaccinations, except for live vaccines (see sections 4.5 and 4.6).
Croatian: Bolesnici koji se liječe infliksimabom mogu istodobno primati cjepiva, osim živih cjepiva (vidjeti dijelove 4.5 i 4.6).
English: Patients received 3 or 6 mg/kg infliximab as a 3-dose induction regimen (weeks 0, 2, 6 or weeks 14, 16, 20 respectively) followed by maintenance therapy every 8 weeks, in combination with methotrexate.
Croatian: Bolesnici su kao uvodnu terapiju primili 3 doze infliksimaba u dozi od 3 mg/kg (u 0., 2. i 6. tjednu) ili 6 mg/kg (u 14., 16. i 20. tjednu), a nakon toga se provodila terapija održavanja svakih 8 tjedana, u kombinaciji s metotreksatom.
English: • treatment of moderately to severely active Crohn's disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.
Croatian: • liječenje umjerenog do teškog oblika aktivne Crohnove bolesti u odraslih bolesnika koji nisu odgovorili na punu i odgovarajuću terapiju nekim kortikosteroidom i/ili imunosupresivom, odnosno u onih koji ne podnose ili imaju medicinske kontraindikacije za takve terapije.
English: The safety and efficacy of Remicade have not been studied in children with Crohn's disease below the age of 6 years.
Croatian: Sigurnost i djelotvornost lijeka Remicade u djece mlađe od 6 godina koja boluju od Crohnove bolesti nisu ispitivani.
English: In the REACH study, 112 patients (6 to 17 years, median age 13.0 years) with moderate to severe, active Crohn's disease (median paediatric CDAI of 40) and an inadequate response to conventional therapies were to receive 5 mg/kg infliximab at weeks 0, 2, and 6.
Croatian: Crohnova bolest u pedijatrijskih bolesnika (6 do 17 godina) U kliničkom ispitivanju REACH, 112 bolesnika (raspon dobi: 6-17 godina, medijan 13 godina) s umjerenom do teškom, aktivnom Crohnovom bolešću (srednji pedijatrijski CDAI bio je 40) i neodgovarajućim odgovorom na konvencionalnu terapiju primilo je infliksimab u dozi od 5 mg/kg u 0., 2. i 6. tjednu.
English: Induction treatment in fistulising active Crohn's disease The efficacy was assessed in a randomised, double-blinded, placebo-controlled study in 94 patients with fistulising Crohn's disease who had fistulae that were of at least 3 months' duration.
Croatian: Djelotvornost lijeka ispitivala se i u randomiziranom, dvostruko slijepom, placebom kontroliranom ispitivanju koje je uključilo 94 bolesnika s fistulirajućim oblikom Crohnove bolesti u kojih su fistule bile prisutne najmanje 3 mjeseca.
English: It is recommended that patients, if possible, be brought up to date with all vaccinations in agreement with current vaccination guidelines prior to initiating Remicade therapy.
Croatian: Preporučuje se da, ako je to moguće, prije početka liječenja lijekom Remicade bolesnici prime sva cjepiva u skladu s važećim smjernicama za cijepljenje.
English: The primary endpoint was the proportion of patients who experienced a clinical response, defined as a decrease in CDAI by ≥ 70 points from baseline at the 4-week evaluation and without an increase in the use of medicinal products or surgery for Crohn's disease.
Croatian: Primarnu mjeru ishoda ispitivanja činio je udio bolesnika koji su pokazali klinički odgovor, definiran kao smanjenje CDAI za ≥ 70 bodova u odnosu na početne vrijednosti nakon 4 tjedna, bez povećanja doza lijekova koji se daju u Crohnovoj bolesti ili kirurškog liječenja Crohnove bolesti.
English: Week 54
Croatian: 54. tjedan
English: The ASPIRE study evaluated responses at 54 weeks in 1,004 methotrexate naive patients with early (≤ 3 years disease duration, median 0.6 years) active rheumatoid arthritis (median swollen and tender joint count of 19 and 31, respectively).
Croatian: U ispitivanju ASPIRE ocjenjivali su se odgovori na terapiju nakon 54 tjedna u 1004 bolesnika s aktivnim reumatoidnim artritisom (medijan broja otečenih zglobova 19, a osjetljivih zglobova 31) u ranoj fazi (trajanje bolesti ≤ 3 godine, medijan 0,6 godina), koji nisu prethodno liječeni metotreksatom.
English: If not used immediately, in use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 °C - 8 °C, unless reconstitution/dilution has been taken place in controlled and validated aseptic conditions.
Croatian: Ako se ne primjeni odmah, trajanje i uvjeti čuvanja do primjene lijeka odgovornost su korisnika i ne bi trebali biti dulji od 24 sata na temperaturi od 2°C do 8°C, osim ukoliko rekonstitucija/razrjeđivanje nije provedeno u kontroliranim i validiranim aseptičkim uvjetima.
English: If you are not sure if any of the above apply to you, talk to your doctor before you are given Remicade.
Croatian: Ako niste sigurni odnosi li se nešto od navedenog na Vas, porazgovarajte sa svojim liječnikom prije nego primite Remicade.
English: Do not infuse Remicade concomitantly in the same intravenous line with other agents.
Croatian: Remicade se ne smije davati istodobno u istoj infuziji s drugim lijekovima.
English: Date of Remicade therapy initiation:
Croatian: Datum početka liječenja lijekom Remicade:
English: The safety and efficacy of Remicade in children and adolescents younger than 18 years for the indication of juvenile rheumatoid arthritis have not been established.
Croatian: Sigurnost i djelotvornost lijeka Remicade u djece i adolescenata mlađih od 18 godina koji boluju od juvenilnog reumatoidnog artritisa nisu još ustanovljene.
English: In both studies, patients were randomised to receive either placebo, 5 mg/kg Remicade, or 10 mg/kg Remicade at weeks 0, 2, 6, 14 and 22, and in ACT 1 at weeks 30, 38 and 46.
Croatian: U oba klinička ispitivanja bolesnici su bili randomizirani u skupine koje su primale placebo, Remicade u dozi od 5 mg/kg ili Remicade u dozi od 10 mg/kg i to u 0., 2., 6., 14. i 22. tjednu, a u ispitivanju ACT 1 još i u 30., 38. i 46. tjednu.
English: • Signs of infection (including TB) such as fever, feeling tired, cough which may be persistent, shortness of breath, flu-like symptoms, weight loss, night sweats, diarrhoea, wounds, collection of pus in the gut or around the anus (abscess), dental problems or burning sensation when urinating.
Croatian: • Znakove infekcije (uključujući TBC) kao što su vrućica, umor, kašalj koji može biti ustrajan, nedostatak zraka, simptomi nalik gripi, gubitak tjelesne težine, noćno znojenje, proljev, rane, nakupljanje gnoja u crijevima ili oko anusa (apsces), problemi sa zubima ili osjećaj žarenja pri mokrenju.
English: Concurrent administration of TNF-alpha inhibitor and abatacept In clinical studies concurrent administration of TNF-antagonists and abatacept has been associated with an increased risk of infections including serious infections compared to TNF-antagonists alone, without increased clinical benefit.
Croatian: U kliničkim ispitivanjima istodobna primjena inhibitora TNFα i abatacepta bila je povezana s povećanim rizikom od razvoja infekcija, uključujući i ozbiljne infekcije, u odnosu na primjenu samo TNF-antagonista, a pritom nije došlo do povećanja kliničkog učinka.
English: If you are given too much Remicade
Croatian: Ako primite previše lijeka Remicade
English: • Treatment with TNF blockers such as Remicade may result in reactivation of hepatitis B
Croatian: • Liječenje TNF-blokatorima kao što je Remicade može izazvati ponovnu aktivaciju virusa hepatitisa B u bolesnika koji nose taj virus, što u nekim slučajevima može ugroziti život.
English: Do not store any unused portion of the infusion solution for reuse.
Croatian: Neiskorišteni dio otopine za infuziju ne smije se čuvati za kasniju primjenu.
English: The median time to onset of response in the infliximab-treated group was 2 weeks.
Croatian: U skupinama liječenima infliksimabom medijan vremena do pojave kliničkog odgovora iznosio je 2 tjedna.
English: Sustained Steroid-Free Remission
Croatian: Održana remisija bez steroida
English: Continued therapy should be carefully reconsidered in patients who show no evidence of therapeutic benefit within this time period.
Croatian: Treba pomno razmotriti nastavak liječenja u bolesnika u kojih se unutar tog razdoblja ne uoče dokazi o koristi terapije.
English: At week 14, 282 patients were assessed for clinical response and randomised to receive either placebo or 5 mg/kg infliximab every 8 weeks through week 46.
Croatian: U 14. je tjednu ocijenjen klinički odgovor 282 bolesnika koji su randomizirani da do 46. tjedna primaju ili placebo ili dozu od 5 mg/kg infliksimaba svakih 8 tjedana.
English: Remicade 100 mg powder for concentrate for solution for infusion infliximab
Croatian: Remicade 100 mg prašak za koncentrat za otopinu za infuziju infliksimab
English: Patients who were randomised to the placebo maintenance group and then later crossed over to infliximab are included in the infliximab group in the ALT analysis.
Croatian: Bolesnici koji su bili randomizirani u skupinu koja je primala placebo tijekom terapije održavanja, a kasnije prebačeni u skupinu koja je primala infliksimab, u svrhu analize ALT-a uključeni su u skupinu koja je primala infliksimab.
English: Infliximab treatment of Crohn's disease patients was also associated with a substantial reduction of the commonly elevated serum inflammatory marker, CRP.
Croatian: Liječenje bolesnika s Crohnovom bolešću infliksimabom također je bilo povezano sa značajnim smanjenjem CRP-a, upalnog biljega čija je koncentracija u serumu tih bolesnika često povećana.